Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients
Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients
复制标题
DOI：
10.1089/cbr.2006.21.22
复制
发表时间：
2006-02-01
影响因子：
3.4
通讯作者：
Hao, XS
中科院分区：
文献类型：
--
作者：
Ren, XB;Yu, JP;Hao, XS
目的：验证自体细胞因子诱导杀伤细胞（Auto-CIKs）治疗实体恶性肿瘤的可行性和有效性。方法：对66例不同病理类型、不同临床阶段实体瘤患者的Auto-CIKs进行大规模临床扩增、表型特征、抗肿瘤细胞毒性、临床免疫反应等检测。结果：我们发现疾病的严重程度和转移状态对Auto-CIKs的有效成分和抗肿瘤活性没有影响。对比LAKs对多种肿瘤细胞的细胞毒性，CIKs对NK敏感和非NK敏感实体肿瘤细胞系的细胞毒性更强，即使在低E/T比（6:1）下也是如此。20例接受多周期Auto-CIKs输注的患者中，3例达到部分缓解（PR）， 14例病情稳定（SD）， 3例死亡。外周血单核细胞（PBMCs）中th1类细胞因子的分泌明显增加，这与多周期输注Auto-CIKs后单核细胞对K562细胞的细胞溶解活性增强有关。结论：Auto-CIKs多周期治疗后在PBMCs中诱导特殊的“Th1偏倚”，提示Auto-CIKs具有免疫促进作用，可能是一种适合于复发风险高的实体恶性肿瘤患者预防复发的免疫治疗方法。
Objective: The aim of this paper was to verify the feasibility and validity of autologous cytokine-induced killer cells (Auto-CIKs) treatments in solid malignancy patients. Methods: Amplification, phenotypic characteristics, antitumor cytotoxicity, and clinical and immunological response of Auto-CIKs derived from 66 cases of patients with solid tumor of different pathological types and at different clinical stages were examined in a large-scale clinical trail. Results: We found that seriousness of disease and metastasis status has no influence on effective components and antitumor activity of Auto-CIKs. Comparing the cytotoxicity against various tumor cells with LAKs, CIKs showed more effective cytotoxicity against NK sensitive and nonsensitive solid tumor cell lines, even at a low E/T ratio (6:1). In 20 patients receiving multicycles of Auto-CIKs infusions, 3 reached partial response (PR), 14 obtained stable disease (SD), and 3 died. Th1-kind cytokines secretion in peripheral blood mononuclear cells (PBMCs increased significantly, according with the enhanced cytolytic activity against K562 cells of them after multicycles of Auto-CIKs infusions. Conclusions: Induction of special "Th1 bias" in PBMCs after multicycles of Auto-CIKs treatments suggested an immunological promoting effect of Auto-CIKs, which seems to be a suitable immunotherapy for those solid-malignance patients who are at high risk of relapse to prevent recurrence.